Skip to main content
. 2019 Jul 12;85(9):1935–1945. doi: 10.1111/bcp.13974

Figure 2.

Figure 2

Covariate effects on HR in the final cox proportional hazards model for PFS (n = 128) in patients with FL participating in GADOLIN who received at least 3 dosing cycles of obinutuzumab (combined with bendamustine). BMINV: bone marrow involvement at baseline; CI: confidence interval; Cmean: mean obinutuzumab exposure over induction period; FL: follicular lymphoma; HR: hazard ratio; PFS: progression‐free survival